看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
+ V: z$ p9 z* F% A, ?3 O" p! e" u2 k! B
! @% ^: K2 R4 _8 ?: S+ Q# d: o
Currently available feasibility data for possible combination strategies. . W8 Y0 K P$ K. J
————————————————————————————————
8 l& {; m7 u1 B* ~Combination Feasibility according to preliminary data & R5 D; y" V* A
——————————————————————————————————. ?6 I# S" c/ ]
Bevacizumab + sorafenib Yes, reduced dose , \4 d- b- E/ a9 |3 W4 o
Bevacizumab + sunitinib† No
9 A- d/ d; E7 pBevacizumab + temsirolimus Yes
0 ^: B4 ]1 ^; n9 [6 hBevacizumab + everolimus Yes * n ^' P2 s8 W; R) O( ~
Sorafenib + sunitinib ? 8 M5 `! R5 v% S
Sorafenib + temsirolimus Yes, reduced dose / j$ g. `2 h+ {
Sorafenib + everolimus Yes, reduced dose
3 b! q: L3 D% N5 P3 I0 i* PSunitinib + temsirolimus† No 3 l" e8 j. _+ P( g8 U
Sunitinib + everolimus ?
2 P+ ~7 ?1 r7 s. rTemsirolimus + everolimus ?
9 m2 f4 C% G+ V6 Z6 t S————————————————————" Q* I7 e6 T0 f! b8 q
†Led to US FDA warning.
1 B* P. [* j; @1 A: v?: As yet unattempted combination.3 y) v6 E0 q3 I0 i$ Y+ H
|